arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BIOLARGO, INC.

BLGO
— Price unavailable
Materials ·Chemicals & Allied Products ·USChemicals & Allied Products
67 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOLARGO, INC. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -55.1% ↗
Op. Margin -298.7% ↘
ROIC 159.0% ↗
FCF / Share $-0.01 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.25M
↓ -55.1% —
Net Income Profit after all expenses
$-4.00M
↓ -112.5% —
Operating Margin Operating profit as % of sales
-298.7%
↓ -4.0% 0th
FCF / Share Free cash flow per share
$-0.01
↓ -4.0% —
Long-Term Debt Long-term obligations
$2.08M
↑ +1055.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Financial Health ↑
36
Cash Quality →
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 67 quarters